ImmunityBio Inc (NASDAQ: IBRX) started the day on Thursday, with a price increase of 6.02% at $5.11, before settling in for the price of $4.82 at the close. Taking a more long-term approach, IBRX posted a 52-week range of $1.25-$6.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 195.19% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 1.17%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 31.75%. This publicly-traded company’s shares outstanding now amounts to $670.87 million, simultaneously with a float of $136.93 million. The organization now has a market capitalization sitting at $3.44 billion. At the time of writing, stock’s 50-day Moving Average stood at $5.19, while the 200-day Moving Average is $3.44.
ImmunityBio Inc (IBRX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. ImmunityBio Inc’s current insider ownership accounts for 79.68%, in contrast to 8.47% institutional ownership. According to the most recent insider trade that took place on Jun 05 ’23, this organization’s Director bought 71,915 shares at the rate of 2.75, making the entire transaction reach 198,023 in total value, affecting insider ownership by 71,915. Preceding that transaction, on Jun 02 ’23, Company’s Director bought 25,000 for 2.83, making the whole transaction’s value amount to 70,700. This particular insider is now the holder of 25,000 in total.
ImmunityBio Inc (IBRX) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 12/31/2023, the organization reported -0.27 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -0.22) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
ImmunityBio Inc’s EPS increase for this current 12-month fiscal period is 31.75% and is forecasted to reach -0.62 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -1.70% through the next 5 years, which can be compared against the 1.17% growth it accomplished over the previous five years trading on the market.
ImmunityBio Inc (NASDAQ: IBRX) Trading Performance Indicators
Let’s observe the current performance indicators for ImmunityBio Inc (IBRX). It’s Quick Ratio in the last reported quarter now stands at 5.05. The Stock has managed to achieve an average true range (ATR) of 0.60. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5554.65.
In the same vein, IBRX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.13, a figure that is expected to reach -0.16 in the next quarter, and analysts are predicting that it will be -0.62 at the market close of one year from today.
Technical Analysis of ImmunityBio Inc (IBRX)
If we take a close look at the recent performances of ImmunityBio Inc (NASDAQ: IBRX), its last 5-days Average volume was 11.45 million that shows progress from its year to date volume of 4.48 million. During the previous 9 days, stock’s Stochastic %D was recorded 26.68% While, its Average True Range was 0.63.
Raw Stochastic average of ImmunityBio Inc (IBRX) in the period of the previous 100 days is set at 54.62%, which indicates a major rise in contrast to 23.75% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 126.51% that was higher than 119.12% volatility it exhibited in the past 100-days period.
